Views 408
Citations 0
Comment & Response
June 2016

Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease—Reply

Author Affiliations
  • 1Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland
  • 2Division of Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia
  • 3Department of Medicine, Johns Hopkins University, Baltimore, Maryland

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2016;176(6):869-870. doi:10.1001/jamainternmed.2016.1863

In Reply We share the concern expressed by Dr Lozano, Iannuzzella et al, Zhao et al, and Drs Ness-Jensen and Fossmark that observational studies may suffer from residual confounding. In the original study,1 to ensure that the observed associations were robust, we performed multiple sensitivity analyses and replicated results in a separate cohort. These analyses included adjustment for many possible confounders, including concomitant medication use, hypertension, body mass index, and diabetes mellitus. We also tested associations using an active comparator group (patients using H2 antagonists), a new-user design, and propensity-score matching. In the latter analysis, matched cohorts were well balanced (Table 1, as requested by Zhao et al), and the study design obviates the concern about multicollinearity that was raised by Drs Ness-Jensen and Fossmark. All sensitivity analyses were consistent and showed an association between proton pump inhibitor (PPI) use and incident chronic kidney disease (CKD).

First Page Preview View Large
First page PDF preview
First page PDF preview